Tidal Investments’s Myriad Genetics MYGN Stock Holding History

Tidal Investments’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-14,550	Closed	-$89.5K	–	2498
2025 Q4	$89.5K	Buy	+14,550	New	+$105K	﹤0.01%	2077
2024 Q2	–	Sell	-28,432	Closed	-$606K	–	1894
2024 Q1	$606K	Buy	+28,432	New	+$611K	0.01%	1107

Other funds holding MYGN

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

GCM

Glenview Capital Management New York $5.49B AUM 46.89% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Tidal Investments's MYGN Position: Q1 2026 in Review

Tidal Investments sold out of Myriad Genetics (MYGN) in Q1 2026, closing a stake of 14,550 shares — an estimated $89.5K sold.

Tidal Investments first reported a position in MYGN in Q1 2024 and held it in 2 quarters. The position peaked at $606K in Q1 2024. 203 funds tracked by Wall St. Rank hold MYGN as of Q1 2026.

Tidal Investments reported no remaining Myriad Genetics position as of Q1 2026 after selling out during the quarter.
Tidal Investments sold 14,550 Myriad Genetics shares in Q1 2026, an estimated $89.5K.
Tidal Investments first reported a position in Myriad Genetics in Q1 2024 and held it in 2 quarters.
Tidal Investments's Myriad Genetics position peaked at $606K in Q1 2024.
203 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2026.

Based on Tidal Investments's 13F filing for Q1 2026, filed 15 May 2026.